May 16 (Reuters) - British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon. (Reporting by Anchal Rana in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,605 GBX | -0.62% | -2.76% | +10.67% |
06-12 | Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says | MT |
06-12 | GSK: licensing agreement with Ochre Bio | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,605 GBX | -0.62% | -2.76% | 83.79B | ||
320.8 GBX | -0.09% | -2.14% | 37.31B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.67% | 83.79B | |
+48.79% | 780B | |
+41.76% | 627B | |
+19.43% | 334B | |
+7.18% | 296B | |
+17.60% | 244B | |
-0.41% | 217B | |
+11.54% | 214B | |
+4.53% | 161B | |
-3.92% | 159B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK intends to sell its entire stake in Haleon